These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 3333088)

  • 1. Erythropoietin--advent of a new treatment.
    Winearls C
    Practitioner; 1987 Oct; 231(1436):1269-73. PubMed ID: 3333088
    [No Abstract]   [Full Text] [Related]  

  • 2. [Improvement of the anemia associated with multiple myeloma and renal dysfunction by recombinant human erythropoietin].
    Nakata H; Matsuzaki M; Shimamoto Y; Yamaguchi M
    Rinsho Ketsueki; 1990 Oct; 31(10):1752-3. PubMed ID: 2255069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Refractory anemia in a patient with allergy to intravenous iron drugs.
    Fishbane S
    Kidney Int; 2006 May; 69(10):1910-3. PubMed ID: 16625145
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment of anemia in myelodysplastic syndromes with recombinant human erythropoietin].
    Rodríguez JN; Prados D; Martino ML; Muñiz R
    Sangre (Barc); 1993 Aug; 38(4):340-1. PubMed ID: 8235952
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiac hemolysis and anemia refractory to erythropoietin: on anemia in dialysis patients.
    Evers J
    Nephron; 1995; 71(1):108. PubMed ID: 8538832
    [No Abstract]   [Full Text] [Related]  

  • 6. [Recombinant human erythropoietin in the treatment of the anemia of multiple myeloma with kidney failure].
    Arenas Gracia M; Abad Gosálvez A; Colomina Avilés J; Pascual Pérez R; Ferriz Moreno P
    An Med Interna; 1995 Apr; 12(4):187-8. PubMed ID: 7620064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined recombinant human erythropoietin-blood letting strategy for treating anemia and iron overload in hemodialysis patients.
    Agroyannis B; Koutsicos D; Tzanatou-Exarchou H; Varsou-Papadimitriou E; Kapetanaki A; Yatzidis H
    Int J Artif Organs; 1991 Jul; 14(7):403-6. PubMed ID: 1889892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of erythropoietin treatment on O2 affinity and performance in patients with renal anemia.
    Böcker A; Reimers E; Nonnast-Daniel B; Kühn K; Koch KM; Scigalla P; Braumann KM; Brunkhorst R; Böning D
    Contrib Nephrol; 1988; 66():165-75. PubMed ID: 3391031
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of recombinant erythropoietin in the treatment of anaemia associated with multiple myeloma in a haemodialysis patient.
    Hussein MM; Mooij JM; Roujouleh H
    Nephrol Dial Transplant; 1994; 9(7):876-7. PubMed ID: 7818713
    [No Abstract]   [Full Text] [Related]  

  • 10. Management of hemosiderosis complicated by coexistent anemia with recombinant human erythropoietin and phlebotomy.
    Bilgrami S; Bartolomeo A; Synnott V; Rickles FR
    Acta Haematol; 1993; 89(3):141-3. PubMed ID: 8362602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recombinant human erythropoietin].
    Frenken LA; Koene RA
    Ned Tijdschr Geneeskd; 1988 Mar; 132(10):432-4. PubMed ID: 3347279
    [No Abstract]   [Full Text] [Related]  

  • 12. [Use of human recombinant erythropoietin (rHuEPO) for treatment of anemia in patients with chronic kidney failure who don't require additional dialysis therapy].
    Wiecek A
    Przegl Lek; 1995; 52(3):93-4. PubMed ID: 7644683
    [No Abstract]   [Full Text] [Related]  

  • 13. r-HuEPO treatment of anemia associated with multiple myeloma and ESRD.
    Van der Niepen P; Sennesael J; Verbeelen D
    Clin Nephrol; 1993 Feb; 39(2):113. PubMed ID: 8448915
    [No Abstract]   [Full Text] [Related]  

  • 14. [Erythropoietin, a milestone in the history of nephrology].
    Uehlinger DE; Frey FJ
    Ther Umsch; 1995 Oct; 52(10):672-7. PubMed ID: 7482378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of recombinant human erythropoietin on the anemia of chronic renal failure.
    Urabe A; Takaku F; Mizoguchi H; Kubo K; Ota K; Shimizu N; Tanaka K; Mimura N; Nihei H; Koshikawa S
    Int J Cell Cloning; 1988 May; 6(3):179-91. PubMed ID: 3397592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The end stage renal disease program.
    Goodkin DA
    N Engl J Med; 1993 Jul; 329(2):140; author reply 140-1. PubMed ID: 8510703
    [No Abstract]   [Full Text] [Related]  

  • 17. Human recombinant erythropoietin: progress in clinical development.
    Kubiak W; Karwacki M; Mazur I
    Ann Univ Mariae Curie Sklodowska Med; 1994; 48 Suppl 3():39-50. PubMed ID: 8192531
    [No Abstract]   [Full Text] [Related]  

  • 18. [Is the index of response to erythropoietin (IRE) a good marker of adequate dialysis?].
    Pérez-García R; Rodríguez-Benítez P; Villaverde MT; Valderrábano F
    Nefrologia; 2001; 21(6):606-7. PubMed ID: 11881433
    [No Abstract]   [Full Text] [Related]  

  • 19. [Resistance to rHuEPO].
    Sułowicz W
    Przegl Lek; 1995; 52(3):88-9. PubMed ID: 7644681
    [No Abstract]   [Full Text] [Related]  

  • 20. [The so-called refractory anemias].
    Frick P
    Schweiz Med Wochenschr; 1987 Sep; 117(36):1347-50. PubMed ID: 3116665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.